This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Strategies for Improving Compliance in Treatment of Schizophrenia by Using a Long-Acting Formulation of an Antipsychotic: Clinical Studies

John M. Kane, MD

Published: November 1, 2003

Article Abstract

Despite evidence showing the importance of continuous medication in preventing relapse in patientswith schizophrenia and the harmful consequences that relapse can have, clinical efforts oftenfocus on hospital-based treatment or treatment of acute exacerbations of schizophrenia rather than onensuring appropriate and effective relapse prevention. Inadequate compliance with antipsychotictreatment further deters from the goal of long-term management of schizophrenia; however, appropriateuse of injectable, long-acting antipsychotic medications—especially atypical antipsychotics—hasthe potential to increase compliance and thus improve the long-term prognosis of patients with schizophrenia.A long-acting formulation of the atypical antipsychotic risperidone has undergone large-scaleclinical testing, during which it showed significant improvement on measures of disease severitywhile maintaining an acceptable side effect profile.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: